MenACWY

BIOLOGICAL9 trials

Conditions

CoronavirusEbola Virus DiseaseInfections, MeningococcalMeningitis, MeningococcalMeningococcal DiseaseSalmonella InfectionsShigellosis

Phase 1

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

CompletedNCT04056117

LimmaTech Biologics AGShigellosis

Start: 2019-09-02End: 2022-11-14Updated: 2024-07-30

A Study of a Candidate COVID-19 Vaccine (COV001)

CompletedNCT04324606

University of OxfordCoronavirus

Start: 2020-04-23End: 2025-02-05Updated: 2025-09-03

Phase 2

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

CompletedNCT02140762

Novartis VaccinesMeningococcal Disease

Start: 2014-05-31End: 2015-02-28Updated: 2018-09-12

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

CompletedNCT03433482

GlaxoSmithKlineMeningitis, Meningococcal

Start: 2018-08-30End: 2019-12-17Updated: 2021-02-17

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

CompletedNCT03929757

Janssen Vaccines & Prevention B.V.Ebola Virus Disease

Start: 2019-08-19End: 2022-09-28Updated: 2025-05-25

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

RecruitingNCT06213506

GlaxoSmithKlineSalmonella Infections

Start: 2024-01-15End: 2026-04-27Target: 516Updated: 2024-01-19

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

CompletedNCT06523231

LimmaTech Biologics AGShigellosis

Start: 2025-04-07End: 2026-01-22Updated: 2026-02-09

Phase 3

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

CompletedNCT02509494

Janssen Vaccines & Prevention B.V.Ebola Virus Disease

Start: 2015-09-30End: 2019-07-03Updated: 2022-07-18

Phase 4

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

CompletedNCT02446691

GlaxoSmithKlineInfections, Meningococcal

Start: 2015-07-13End: 2017-12-28Updated: 2019-06-27

Nature Communications2024-04-2223 citations

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

PLoS neglected tropical diseases2024-04-111 citations

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.

2023-11-017 citations

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

Vaccines2023-08-024 citations

Re‐randomization tests as sensitivity analyses to confirm immunological noninferiority of an investigational vaccine: Case study

Pharmaceutical Statistics2023-01-272 citations

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

2022-12-0532 citations

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.

2022-11-3014 citations

Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis

Drug Safety2022-11-112 citations

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens

Frontiers in Immunology2022-10-0515 citations

Synergistic activity of antibodies in the multicomponent 4CMenB vaccine.

2022-03-1421 citations

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

2021-12-207 citations

632. Clinical Experience with a New Fully Liquid Presentation of the MenACWY-CRM Vaccine. Results from Two Multicenter, Randomized, Controlled, Observer-Blind, Phase 2b Studies

Open Forum Infectious Diseases2021-11-01

Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults

Human Vaccines & Immunotherapeutics2021-10-065 citations

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

2021-09-1361 citations

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.

2021-09-1359 citations

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

2021-09-01208 citations

Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol

BMJ Open2021-09-0125 citations

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Nature Communications2021-07-3057 citations

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

EBioMedicine2021-04-0177 citations

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

2021-02-19903 citations

8 more papers not shown